125 related articles for article (PubMed ID: 38797993)
1. Downstaging with Atezolizumab-Bevacizumab: A Case Series.
Kulkarni AV; P K; Menon B; Sekaran A; Rambhatl A; Iyengar S; Alla M; Venishetty S; Ramachandra SK; V PG; Sharma M; Rao PN; Reddy DN; Singal AG
J Liver Cancer; 2024 May; ():. PubMed ID: 38797993
[TBL] [Abstract][Full Text] [Related]
2. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
3. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
[TBL] [Abstract][Full Text] [Related]
10. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
[TBL] [Abstract][Full Text] [Related]
11. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O
J Interv Med; 2023 Nov; 6(4):187-193. PubMed ID: 38312131
[TBL] [Abstract][Full Text] [Related]
12. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
13. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38678485
[TBL] [Abstract][Full Text] [Related]
14. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Kawano Y; Morishita A; Okamoto K; Sogabe M; Miyamoto H; Masaki T; Takayama T
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958395
[TBL] [Abstract][Full Text] [Related]
16. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
Singal AG; Özgürdal K; Fan X; Vassilev Z; Pan X; Multani JK; Chen CC; Zhou Z; He J; Pisa F
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067235
[TBL] [Abstract][Full Text] [Related]
17. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
[TBL] [Abstract][Full Text] [Related]
18. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chiang CL; Chan SK; Lee SF; Choi HC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
20. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yamauchi Y; Saeki I; Yamasaki T; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Nishimura T; Tanabe N; Oono T; Matsumoto T; Ishikawa T; Marumoto Y; Matsukuma S; Shindo Y; Tokumitsu Y; Yoshimine S; Murakami J; Tanaka T; Kimura S; Hoshii Y; Hamano K; Nagano H; Takami T
Hepatol Res; 2023 Jul; 53(7):681-686. PubMed ID: 36826420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
